👉 𝑵𝒂𝒗𝒊𝒈𝒂𝒕𝒊𝒏𝒈 𝒕𝒉𝒆 𝑫𝒊𝒈𝒊𝒕𝒂𝒍 𝑭𝒓𝒐𝒏𝒕𝒊𝒆𝒓: Highlights from a Day of Insightful Discourse on Digital Technologies in Biotech and Biopharma event on Campus Energypolis. It was an amazing opportunity to learn from experts and peers in the D-A-CH region about how digitalization, data science, artificial intelligence (AI), and machine learning (ML) are transforming biotechnology and biopharma.
Navigating the Digital Frontier Read More »
From its beginnings as a small company in Aargau to its rise as a global CDMO leader, Siegfried embodies strategic growth, innovation and a strong commitment to pharmaceutical sustainability.
Siegfried, a Swiss leader taking innovations to industrial scale Read More »
Orio Therapeutics, a start-up based at Monthey’s BioArk, has won the CHF 40,000 prize alongside KIDEMIS and Rheo, with a project designed to reduce drug use, costs and side-effects, while improving therapeutic outcomes. Proud to be one of the three winners of this second stage of Venture Kick, Orio Therapeutics had to demonstrate the solidity
Orio Therapeutics, finalist of Venture Kick’s 2nd stage! Read More »
EPFL and Novochizol SA to collaborate on designing more efficient immunotherapies, with the support of Innosuisse, the Swiss Innovation Agency. The EPFL Laboratory of Biomaterials for Immunoengineering, headed by Prof. Li Tang, and the BioArk Monthey– hosted startup company Novochizol SA possessing a unique chitosan transformation technology, today announced that Innosuisse will co-fund their collaborative
Cancer Research: CHF 1.1 Million for Novochizol SA Read More »
One of the major events for virtual business development and licensing is back, from November 27th to December 1st, 2023. As a partner of the event, BioArk is pleased to offer Valais life science actors a promo code to participate and enhance their business opportunities! The Biotechgate Digital Partnering virtual event is designed to support
Biotechgate Digital Partnering is back in November Read More »
Debiopharm is to build a new Innovation building dedicated to research and development at its Valais site in Martigny. The Lausanne-based biopharmaceutical group will invest CHF 30 million in the project…
Debiopharm invests over 30 million francs in innovation in Martigny Read More »
From dynamite to pharmaceuticals, Valsynthèse, the ‘fine chemistry’ business unit of the Société Suisse des Explosifs, celebrates four decades of steering innovative chemical solutions in Valais.
Valsynthèse, 40 years of innovation in the canton of Valais Read More »
BioArk is on a roll! The Monthey-based technology site, which celebrates its 20th anniversary this year, inaugurated its third building on Friday.
BioArk’s third building in Monthey has just been inaugurated and is already almost full! Read More »
The pharmaceutical and biotechnology group Lonza has confirmed the extension of a long-term collaboration with a major global biopharmaceutical partner. The agreement will quadruple current bioconjugation capacity at the Ibex facilities in Visp. The new suites are expected to be operational in 2026 and will generate approximately 180 jobs, according to Lonza.
Lonza plan to create 180 jobs in Visp by 2026 Read More »
The Institute of Life Technologies of the School of Engineering of the HES-SO Valais-Wallis has sealed…
